Who we are
About the project
News
Questions
Who we are
About the project
News
Questions
Galerie Partenaires - My Gallery
<
>
MagIA diagnostics
Founded in 2017, MagIA diagnostics provides a groundbreaking Point-Of-Care solution for rapid and combined STI screening at the fingertip. Built on Magnetic ImmunoAssay technology developed by CNRS and Grenoble Alpes University laboratories, MagIA benefits from 15 years of research to locally capture nanoparticles onto micromagnets. This innovation allows massive immunoassay parallelization without complex fluid handling, enabling cost-effective production of consumables. Our involvement: As a project leader, responsible for POCT IBC IBS and TREATB kit development & manufacturing, along with analyzer assembling (CDMO), calibration, and software development.
  • Paul KAUFFMANN (Project manager)
  • Cédric BRUIX
  • Sarah DELSHADI
  • Mario FRATZL
Country Map
MagIA diagnostics GAVIES INSTITUT PASTEUR PAC-CI BIOCARE KEMRI FARAM
Galerie Partenaires - My Gallery
<
>
MagIA diagnostics
Founded in 2017, MagIA diagnostics provides a groundbreaking Point-Of-Care solution for rapid and combined STI screening at the fingertip. Built on Magnetic ImmunoAssay technology developed by CNRS and Grenoble Alpes University laboratories, MagIA benefits from 15 years of research to locally capture nanoparticles onto micromagnets. This innovation allows massive immunoassay parallelization without complex fluid handling, enabling cost-effective production of consumables. Our involvement: As a project leader, responsible for POCT IBC IBS and TREATB kit development & manufacturing, along with analyzer assembling (CDMO), calibration, and software development.
  • Paul KAUFFMANN (Project manager)
  • Cédric BRUIX
  • Sarah DELSHADI
  • Mario FRATZL
MagIA diagnostics GAVIES Institut Pasteur PAC-CI BIOCARE KEMRI FARAM
Galerie Partenaires - My Gallery
<
>
Partenaire 1 Partenaire 2 Partenaire 3 Partenaire 4 Partenaire 5 Partenaire 6 Partenaire 7
Founded in 2017, MagIA diagnostics provides a groundbreaking Point-Of-Care solution for rapid and combined STI screening at the fingertip. Built on Magnetic ImmunoAssay technology developed by CNRS and Grenoble Alpes University laboratories, MagIA benefits from 15 years of research to locally capture nanoparticles onto micromagnets. This innovation allows massive immunoassay parallelization without complex fluid handling, enabling cost-effective production of consumables. Our involvement: As a project leader, responsible for POCT IBC IBS and TREATB kit development & manufacturing, along with analyzer assembling (CDMO), calibration, and software development.
  • Paul KAUFFMANN (Project manager)
  • Cédric BRUIX
  • Sarah DELSHADI
  • Mario FRATZL
Project presentation

Antenatal screening in Sub-Saharan Africa faces a critical gap: today, testing for infectious diseases is still predominantly limited to HIV. However, the World Health Organization (WHO) recommends combining HIV screening with tests for Syphilis and viral Hepatitis. Currently, these screenings are conducted using individual strip tests.

Handling multiple rapid tests in parallel presents several challenges. These include usability issues such as multiple finger pricks and varying incubation times, which are difficult to manage during a consultation and can lead to potential errors. Additionally, storing multiple rapid tests in primary care settings poses logistical constraints due to the varying shelf lives and storage requirements of these tests.

For these reasons, the WHO supports the development of multiplex tests.

Regions such as Sub-Saharan Africa face additional challenges due to financial constraints. When a screening test for Hepatitis B is positive, referral for treatment requires additional analyses to guide treatment decisions. This testing is performed in laboratories, is expensive, and is often unaffordable for pregnant women.

As part of the MAGFA project, financed by EDCTP3, MagIA diagnostics and its partners aim to develop a combined screening panel for HIV, viral Hepatitis, and Syphilis, called MagIA H³S, specifically for pregnant women. Additionally, they will develop a MagIA TREATB panel to refer HBV-infected pregnant women for prophylactic treatment to prevent perinatal transmission of the virus. This rapid “TEST & TREAT” approach during a single consultation will significantly reduce the risk of mother-to-child transmission.

To evaluate and validate this approach, clinical validation will be performed on a large cohort of samples in central labs. The tests will then be evaluated during perinatal consultations involving 7,500 pregnant women across four provinces in the Democratic Republic of the Congo (DRC). This evaluation will demonstrate the feasibility and impact of integrating such a “TEST & TREAT” approach into routine antenatal care.

Logo_EDCTP
HIV
SYPHILIS
HBV
Coverage of antenatal screening in Sub-Saharan Africa
83% of pregnant women tested
47% of pregnant women tested
<1% of pregnant women tested
Impact in Sub-Saharan Africa
120,000 new infections in children
216,000 cases of congenital Syphilis
360,000 new infections in infants
Discover our latest news

Latest news

    Stay informed with the latest updates!

    Click here for the latest news

    News

    Get in
    touch

      Please feel free to ask any questions!

      Accessibilité : partiellement conforme | Accessibility: partially compliant